Grail (NASDAQ:GRAL) Research Coverage Started at Wolfe Research

Wolfe Research started coverage on shares of Grail (NASDAQ:GRAL) in a research note released on Friday morning, MarketBeat reports. The firm issued a peer perform rating on the stock.

Separately, Guggenheim initiated coverage on Grail in a research report on Thursday, October 17th. They issued a “neutral” rating on the stock.

Grail Stock Down 6.4 %

Grail stock opened at $14.80 on Friday. Grail has a 52 week low of $12.33 and a 52 week high of $23.36. The firm has a fifty day simple moving average of $13.82.

Insiders Place Their Bets

In other news, CEO Robert P. Ragusa sold 123,454 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now directly owns 612,661 shares of the company’s stock, valued at approximately $8,589,507.22. The trade was a 16.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Chun R. Ding bought 16,200 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The stock was purchased at an average price of $12.92 per share, with a total value of $209,304.00. Following the completion of the purchase, the insider now directly owns 3,644,855 shares of the company’s stock, valued at approximately $47,091,526.60. This trade represents a 0.45 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 58,829 shares of company stock worth $757,298 over the last quarter.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.